Unknown

Dataset Information

0

A Novel Tomato-Soy Juice Induces a Dose-Response Increase in Urinary and Plasma Phytochemical Biomarkers in Men with Prostate Cancer.


ABSTRACT:

Background

Tomato and soy intake is associated with reduced prostate cancer risk or severity in epidemiologic and experimental studies.

Objective

On the basis of the principle that multiple bioactives in tomato and soy may act on diverse anticancer pathways, we developed and characterized a tomato-soy juice for clinical trials. In this phase 2 dose-escalating study, we examined plasma, prostate, and urine biomarkers of carotenoid and isoflavone exposure.

Methods

Men scheduled for prostatectomy were recruited to consume 0, 1, or 2 cans of tomato-soy juice/d before surgery (mean ± SD duration: 24 ± 4.6 d). The juice provided 20.6 mg lycopene and 66 mg isoflavone aglycone equivalents/177-mL can. Plasma carotenoids and urinary isoflavone metabolites were quantified by HPLC-photometric diode array and prostate carotenoids and isoflavones by HPLC-tandem mass spectrometry.

Results

We documented significant dose-response increases (P < 0.05) in plasma concentrations of tomato carotenoids. Plasma concentrations were 1.86-, 1.69-, 1.73-, and 1.69-fold higher for lycopene, β-carotene, phytoene, and phytofluene, respectively, for the 1-can/d group and 2.34-, 3.43-, 2.54-, and 2.29-fold higher, respectively, for the 2-cans/d group compared with 0 cans/d. Urinary isoflavones daidzein, genistein, and glycitein increased in a dose-dependent manner. Prostate carotenoid and isoflavone concentrations were not dose-dependent in this short intervention; yet, correlations between plasma carotenoid and urinary isoflavones with respective prostate concentrations were documented (R2 = 0.78 for lycopene, P < 0.001; R2 = 0.59 for dihydrodaidzein, P < 0.001). Secondary clustering analyses showed urinary isoflavone metabolite phenotypes. To our knowledge, this is the first demonstration of the phytoene and phytofluene in prostate tissue after a dietary intervention. Secondary analysis showed that the 2-cans/d group experienced a nonsignificant decrease in prostate-specific antigen slope compared with 0 cans/d (P = 0.078).

Conclusion

These findings provide the foundation for evaluating a well-characterized tomato-soy juice in human clinical trials to define the impact on human prostate carcinogenesis. This trial is registered at clinicaltrials.gov as NCT01009736.

SUBMITTER: Grainger EM 

PROVIDER: S-EPMC6351139 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Novel Tomato-Soy Juice Induces a Dose-Response Increase in Urinary and Plasma Phytochemical Biomarkers in Men with Prostate Cancer.

Grainger Elizabeth M EM   Moran Nancy E NE   Francis David M DM   Schwartz Steven J SJ   Wan Lei L   Thomas-Ahner Jennifer J   Kopec Rachel E RE   Riedl Ken M KM   Young Gregory S GS   Abaza Ronney R   Bahnson Robert R RR   Clinton Steven K SK  

The Journal of nutrition 20190101 1


<h4>Background</h4>Tomato and soy intake is associated with reduced prostate cancer risk or severity in epidemiologic and experimental studies.<h4>Objective</h4>On the basis of the principle that multiple bioactives in tomato and soy may act on diverse anticancer pathways, we developed and characterized a tomato-soy juice for clinical trials. In this phase 2 dose-escalating study, we examined plasma, prostate, and urine biomarkers of carotenoid and isoflavone exposure.<h4>Methods</h4>Men schedul  ...[more]

Similar Datasets

| S-EPMC6398392 | biostudies-literature
| S-EPMC10178207 | biostudies-literature
| S-EPMC6520770 | biostudies-literature
2023-05-13 | E-MTAB-12095 | biostudies-arrayexpress
| S-EPMC7432079 | biostudies-literature
| S-EPMC3279611 | biostudies-literature
| S-EPMC4227612 | biostudies-literature
| S-EPMC7224633 | biostudies-literature
| S-EPMC3750717 | biostudies-literature
| S-EPMC11394243 | biostudies-literature